Stimulant use following the publicity of cardiovascular safety and the introduction of patient medication guides-Reference-Cited by-同舟云学术

Stimulant use following the publicity of cardiovascular safety and the introduction of patient medication guides

Published:2015-11-23 Issue:6 Volume:25 Page:678-686
ISSN:1053-8569
Container-title:Pharmacoepidemiology and Drug Safety
language:en
Short-container-title:Pharmacoepidemiol Drug Saf

Author:

Chen Chih-Ying¹,Bussing Regina²³⁴⁵⁶,Hartzema Abraham G.¹,Shuster Jonathan J.⁷⁸,Segal Richard⁹¹⁰,Winterstein Almut G.¹¹¹

Affiliation:

1. Department of Pharmaceutical Outcomes and Policy, College of Pharmacy; University of Florida; Gainesville FL USA

2. Division of Child and Adolescent Psychiatry; University of Florida; Gainesville FL USA

3. Department of Psychiatry; University of Florida; Gainesville FL USA

4. Department of Pediatrics; University of Florida; Gainesville FL USA

5. Department of Clinical and Health Psychology; University of Florida; Gainesville FL USA

6. Department of Epidemiology and Health Policy Research; University of Florida; Gainesville FL USA

7. Department of Health Outcomes and Policy, College of Medicine; University of Florida; Gainesville FL USA

8. Research Design and Analysis Program; University of Florida Clinical and Translational Science Institutes; Gainesville FL USA

9. Department of Pharmaceutical Outcomes and Policy, Department of Pharmacotherapy and Translational Research; University of Florida; Gainesville FL USA

10. Department of Health Services Research, Management, and Policy, College of Public Health and Health Professions; University of Florida; Gainesville FL USA

11. Department of Epidemiology, Colleges of Medicine and Public Health and Health Professions; University of Florida; Gainesville FL USA

Funder

National Center for Translational Sciences, National Institutes of Health (NIH)

Publisher

Wiley

Subject

Pharmacology (medical),Epidemiology

Reference23 articles.

1. Health Canada Health Canada Important Safety Information on ADDERALL XR™ (amphetamine salts) 2005

2. Health Canada Health Canada Important Safety Information on ADDERALL XR™ (amphetamine salts) 2005

3. FDA Pediatric Advisers Say Nay to ADHD Drug Black Box 2013

4. FDA Public Health Advisory for Adderall and Adderall XR 2013

5. ADHD drugs and cardiovascular risk;Nissen;N Engl J Med,2006

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Using Joinpoint regression for drug utilization research: Tutorial and case study of prescription opioid use in the United States;Pharmacoepidemiology and Drug Safety;2023-03-02

2. Topiramate Utilization After Phentermine/Topiramate Approval for Obesity Management: Risk Minimization in the Era of Drug Repurposing;Drug Safety;2022-11-01

3. Association of US Food and Drug Administration Removal of Indications for Use of Oral Quinolones With Prescribing Trends;JAMA Internal Medicine;2021-06-01

4. Safety of ibuprofen in infants younger than six months: A retrospective cohort study;PLOS ONE;2018-06-28

5. Stimulants and Pediatric Cardiovascular Risk;Journal of Child and Adolescent Psychopharmacology;2017-08